申请人:Japan Tobacco Inc.
公开号:US06017919A1
公开(公告)日:2000-01-25
The compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.
公式(I)##STR1##中的化合物,其中每个符号如说明书中所定义,其药用可接受的盐及其医药用途。本发明的化合物(I)及其药用可接受的盐对大麻素受体具有选择性作用,尤其是外周受体,对中枢系统的副作用较小,并且具有卓越的免疫调节作用、抗炎作用、抗过敏作用和对肾炎的治疗效果。因此,它们作为大麻素受体,尤其是外周大麻素受体的激动剂和拮抗剂,免疫调节剂,自身免疫性疾病的治疗剂,抗炎剂,抗过敏剂和肾炎的治疗剂是有用的。